Red Blood Cell Nanosponge (RBC-NS)
RBC-NS are red blood cell membrane nanoparticles.
One red blood cell can be made into thousands of RBC-NS. RBC-NS has all the membrane lipids and receptors that a natural red blood cell has and can work as a decoy for red blood cells. Biomolecules such as toxins and auto-antibodies that attack red blood cells are more likely to bind to RBC-NS and be neutralized due to the larger surface-volume ratio of RBC-NS. This allows RBC-NS to have a broad application in numerous bacterial infections and hemolytic autoimmune diseases. One of the bacterial infections that RBC-NS can address is Methicillin Resistance Staphylococcus Aureus (MRSA). The pore-forming toxins emitted by MRSA can be effectively absorbed and neutralized by RBC-NS. Cellics’ lead drug candidate CTI-005 is for the treatment of MRSA Pneumonia and is IND submission ready. This important milestone validates and de-risks the Cellular Nanosponge Platform and can also guide the development path of all future Nanosponge drug candidates including those of Macrophage Nanosponge. Other indications can leverage the toxicology program of CTI-005. Cellics in-house GMP facility and formulation and manufacturing experience from CTI-005 will also facilitate the manufacturing of drug products for other indications.
Current RBC-NS Pipeline includes the following indications: